Roche Holding AG

We maintain a bullish medium-term stance as the stock remains in Stage 2 corrective reset, holding above the 9/20 EMA convergence and the rising 50 DMA, with the long-term uptrend intact. Near-term, price is range-bound and tightly tracking flat EMAs, offering no clear execution edge. We will stalk pullbacks into the EMA and 50 DMA confluence as our preferred entry zone. Key risks include a decisive break below these EMAs and 50 DMA support, which would signal deeper corrective risk and invalidate the bullish posture.

• ↑Pharma revenue reached CHF 35.6 B, up 9% YoY; international sales +13%.
• ↑10 pipeline molecules moved into Phase III, signaling robust R&D momentum.
• ↓Diagnostics revenues plunged 27% in China; single-digit decline expected in 2025.